{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:23:14Z","timestamp":1700526194224},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vitiligo is reported to affect 2% of the world\u2019s population and has a significant impact on health related quality of life (HRQoL). The relationship between HRQoL and clinical outcomes used in vitiligo require further examination. Mapping condition specific measures of HRQoL: vitiligo specific quality of life instrument (VitiQoL), vitiligo noticeability scale (VNS) and vitiligo re-pigmentation scores (RPS) to the EQ-5D have not yet been reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data collected from a randomised clinical trial (HI-Light) in vitiligo was used to develop mapping algorithms for the EQ-5D-5\u00a0L and the relationship between HRQoL, clinical outcomes and EQ-5D were investigated. Two EQ-5D-5\u00a0L value sets (Van Hout and Alava) using linear and non-linear models were considered. Logistic regression models were used to model the probability of vitiligo noticeability (VNS) in terms of RPS, EQ-5D and VitiQoL scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mapping from RPS appeared to perform better followed by VNS for the Alava crosswalks using polynomial models: Mean observed vs. predicted utilities of 0.9008 (0.005) vs. 0.8984 (0.0004) were observed for RPS. For VNS, mean observed vs. predicted utilities of 0.9008 (0.005) vs. 0.8939 (0.0003) were observed. For VitiQoL, mean observed vs. predicted utilities of 0.9008 (0.005) vs. 0.8912 (0.0002) were observed. For patients with the least re-pigmentation (RPS\u2009&lt;\u200925%), a Total VitiQoL score of about 20 points gives around an 18% chance of vitiligo being no longer or a lot less noticeable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The algorithm based on RPS followed by VNS performed best. The relationship between effects from vitiligo specific HRQoL instruments and clinical RPS was established allowing for plausible clinically relevant differences to be identified, although further work is required in this area.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12955-023-02172-4","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T05:01:59Z","timestamp":1691643719000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating health related quality of life effects in vitiligo. Mapping EQ-5D-5\u00a0L utilities from vitiligo specific scales: VNS, VitiQoL and re-pigmentation measures using data from the HI-Light trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Rabiah","family":"Begum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Crott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reynaldo","family":"Martina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni M.","family":"Loizidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iftekhar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"2172_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1111\/bjd.19592","volume":"184","author":"KS Thomas","year":"2021","unstructured":"Thomas KS, Batchelor JM, Akram P, Chalmers JR, Haines RH, Meakin GD, Duley L, Ravenscroft JC, Rogers A, Sach TH, Santer M, Tan W, White J, Whitton ME, Williams HC, Cheung ST, Hamad H, Wright A, Ingram JR, Levell NJ, Goulding JMR, Makrygeorgou A, Bewley A, Ogboli M, Stainforth J, Ferguson A, Laguda B, Wahie S, Ellis R, Azad J, Rajasekaran A, Eleftheriadou V, Montgomery AA and. Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial*. Br J Dermatol. 2021;184:828\u201339. https:\/\/doi.org\/10.1111\/bjd.19592.","journal-title":"Br J Dermatol"},{"key":"2172_CR2","unstructured":"EuroQol Research Foundation. EQ-5D-5L User Guide., 2019. Available from: https:\/\/euroqol.org\/publications\/user-guides."},{"key":"2172_CR3","unstructured":"Longworth L, Rowen DNICEDSU. Technical Support Document 10: The use of mapping methods to estimate health state utility values. 2011. Available from http:\/\/www.nicedsu.org.uk."},{"key":"2172_CR4","unstructured":"Wailoo A, Hernandez Alava M, Pudney SNICEDSU. Technical Support Document 22 Mapping to estimate health state utilities. 2023 [Available from http:\/\/www.nicedsu.org.uk]."},{"key":"2172_CR5","unstructured":"Guidelines for\u00a0the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.\u00a0https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition."},{"key":"2172_CR6","unstructured":"Guidelines PBAC. 2016, PBAC Guidelines Version 5.0. Available from https:\/\/pbac.pbs.gov.au\/."},{"key":"2172_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12955-016-0455-1","volume":"14","author":"I Khan","year":"2016","unstructured":"Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14:60. https:\/\/doi.org\/10.1186\/s12955-016-0455-1. PMID: 27072351; PMCID: PMC4830017.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2172_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","volume":"11","author":"JE Brazier","year":"2010","unstructured":"Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215\u201325. https:\/\/doi.org\/10.1007\/s10198-009-0168-z. Epub 2009 Jul 8. PMID: 19585162.","journal-title":"Eur J Health Econ"},{"key":"2172_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1477-7525-7-27","volume":"7","author":"D Rowen","year":"2009","unstructured":"Rowen D, Brazier J, Roberts J, Mapping. SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes. 2009;7:27. https:\/\/doi.org\/10.1186\/1477-7525-7-27.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"2172_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. The MAPS Reporting Statement for Studies Mapping onto generic preference-based outcome measures: explanation and elaboration. PharmacoEconomics. 2015;33(10):993\u20131011. https:\/\/doi.org\/10.1007\/s40273-015-0312-9. PMID: 26232200.","journal-title":"PharmacoEconomics"},{"key":"2172_CR11","doi-asserted-by":"publisher","unstructured":"Hagiwara Y, Kawahara T, Shiroiwa T, What. Value Health. 2020;23(9):1218\u201324. https:\/\/doi.org\/10.1016\/j.jval.2020.03.020. Epub 2020 Aug 1. PMID: 32940240. Is a Valid Mapping Algorithm in Cost-Utility Analyses? A Response From a Missing Data Perspective.","DOI":"10.1016\/j.jval.2020.03.020"},{"key":"2172_CR12","doi-asserted-by":"publisher","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6. Doi: https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x. PMID: 8033378.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"issue":"1","key":"2172_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jdv.18593","volume":"37","author":"PV Chernyshov","year":"2023","unstructured":"Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE, Bewley A, Svensson A, Poot F, Suru A, Salek SS, Augustin M, Szepietowski J, Koumaki D, Katoulis AC, Sampogna F, Abeni D, Linder DM, Speeckaert R, van Geel N, Seneschal J, Ezzedine K, Finlay AY. Quality of life measurement in vitiligo. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient oriented Outcomes with external experts. J Eur Acad Dermatol Venereol. 2023;37(1):21\u201331. https:\/\/doi.org\/10.1111\/jdv.18593. Epub 2022 Oct 19. PMID: 36259656.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2172_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/0378-6323.107637","volume":"79","author":"GS Krishna","year":"2013","unstructured":"Krishna GS, Ramam M, Mehta M, Sreenivas V, Sharma VK, Khandpur S. Vitiligo impact scale: an instrument to assess the psychosocial burden of vitiligo. Indian J Dermatol Venereol Leprol. 2013;79:205\u201310.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"2172_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.13432","volume":"172","author":"L Komen","year":"2015","unstructured":"Komen L, da Gra\u00e7a V, Wolkerstorfer A, de Rie MA, Terwee CB, van der Veen JP. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol. 2015;172(2):437\u201343. https:\/\/doi.org\/10.1111\/bjd.13432. Epub 2015 Jan 8. PMID: 25278165.","journal-title":"Br J Dermatol"},{"key":"2172_CR16","doi-asserted-by":"publisher","unstructured":"Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2012.01.038. Epub 2012 Feb 25.","DOI":"10.1016\/j.jaad.2012.01.038"},{"issue":"2","key":"2172_CR17","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bjd.14208","volume":"174","author":"JM Batchelor","year":"2016","unstructured":"Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. Br J Dermatol. 2016;174(2):386\u201394. https:\/\/doi.org\/10.1111\/bjd.14208. Epub 2015 Dec 14. PMID: 26409256; PMCID: PMC5019146.","journal-title":"Br J Dermatol"},{"key":"2172_CR18","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s11136-017-1607-4","volume":"26","author":"F Ali","year":"2017","unstructured":"Ali F, Kay R, Finlay A, Piguet V, Kupfer J, Dalgard F, et al. Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression. Qual Life Res. 2017;26:3025\u201334.","journal-title":"Qual Life Res"},{"issue":"9","key":"2172_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","volume":"29","author":"AW Vilsb\u00f8ll","year":"2020","unstructured":"Vilsb\u00f8ll AW, Hahn-Pedersen NKraghJ. Cathrine Elgaard Jensen ; Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study. Qual Life Res. 2020;29(9):2529\u201339.","journal-title":"Qual Life Res"},{"issue":"S2","key":"2172_CR20","first-page":"7","volume":"132","author":"MKA Basra","year":"2012","unstructured":"Basra MKA, Cruz P, Finlay A, Yule, Piguet V, Salek Mir-saeed. The Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D): is there a correlation between these two measures? [Abstract]. J Invest Dermatology. 2012;132(S2):7.","journal-title":"J Invest Dermatology"},{"key":"2172_CR21","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jval.2017.10.024","volume":"21","author":"N Davison","year":"2018","unstructured":"Davison N, Thompson A, Turner A, Longworth L, McElhone K, Griffiths C, et al. Generating EQ-5D-3L utility scores from the Dermatology Life Quality Index: a mapping study in patients with psoriasis. Value in Health. 2018;21:1010\u20138.","journal-title":"Value in Health"},{"issue":"4","key":"2172_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10778.x","volume":"166","author":"JM Norlin","year":"2012","unstructured":"Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166(4):797\u2013802. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10778.x. Epub 2012 Mar 12. PMID: 22182212.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2172_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00403-012-1309-2","volume":"305","author":"C Blome","year":"2013","unstructured":"Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res. 2013;305(3):197\u2013204. https:\/\/doi.org\/10.1007\/s00403-012-1309-2. Epub 2012 Dec 25. PMID: 23266843.","journal-title":"Arch Dermatol Res"},{"issue":"Suppl 1","key":"2172_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10198-014-0600-x","volume":"15","author":"E Her\u00e9di","year":"2014","unstructured":"Her\u00e9di E, Rencz F, Balogh O, Gul\u00e1csi L, Hersz\u00e9nyi K, Holl\u00f3 P, J\u00f3kai H, K\u00e1rp\u00e1ti S, P\u00e9ntek M, Remenyik \u00c9, Szegedi A, Brodszky V. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014;15(Suppl 1):111\u20139. https:\/\/doi.org\/10.1007\/s10198-014-0600-x. Epub 2014 May 16. PMID: 24832842.","journal-title":"Eur J Health Econ"},{"key":"2172_CR25","doi-asserted-by":"publisher","unstructured":"Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012 Jul-Aug;15(5):708\u201315. Doi: https:\/\/doi.org\/10.1016\/j.jval.2012.02.008. Epub 2012 May 24. PMID: 22867780.","DOI":"10.1016\/j.jval.2012.02.008"},{"key":"2172_CR26","unstructured":"Position statement on use of the EQ-5D-5L value set for England (updated. October 2019). Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l."},{"key":"2172_CR27","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study. PharmacoEconomics (2022). https:\/\/doi.org\/10.1007\/s40273-022-01218-7.","DOI":"10.1007\/s40273-022-01218-7"},{"key":"2172_CR28","doi-asserted-by":"publisher","unstructured":"Donna Rowen C, Mukuria N, Bray J, Carlton L, Longworth D, Meads, Ciaran O\u2019Neill K, Shah Y, Yang. Assessing the comparative feasibility, acceptability and equivalence of videoconference interviews and face-to-face interviews using the time trade-off technique, Social Science & Medicine, Volume\u00a0309, 2022,115227, ISSN 0277\u20139536, Available from: https:\/\/doi.org\/10.1016\/j.socscimed.2022.115227.","DOI":"10.1016\/j.socscimed.2022.115227"},{"key":"2172_CR29","doi-asserted-by":"publisher","unstructured":"Gelman A, Hwang J, Vehtari A. Understanding predictive information criteria for bayesian models. Stat Comput. 2013;24. https:\/\/doi.org\/10.1007\/s11222-013-9416-2.","DOI":"10.1007\/s11222-013-9416-2"},{"key":"2172_CR30","unstructured":"Ratkowsky DA. Handbook of nonlinear regression models. Marcel Dekker, New York; 1990."},{"key":"2172_CR31","volume-title":"SAS\u00ae OnDemand for Academics: user\u2019s guide","author":"SAS Institute Inc","year":"2022","unstructured":"SAS Institute Inc. SAS\u00ae OnDemand for Academics: user\u2019s guide. Cary, NC: SAS Institute Inc; 2022."}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-023-02172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-023-02172-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-023-02172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:03:27Z","timestamp":1700517807000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-023-02172-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2172"],"URL":"https:\/\/doi.org\/10.1186\/s12955-023-02172-4","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The HI-Light study was approved by the Health Research Authority East Midlands (Derby) Research Ethics Committee (14\/EM\/1173) and the Medicines and Healthcare products Regulatory Agency (EudraCT 2014-003473-42).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}